News Industry News New Haven Pharmaceuticals Presents Positive Data That Shows DURLAZA™ is Well Tolerated and Delivers Sustained 24-hour Antiplatelet Control March 01, 2016
News Industry News New Haven Pharmaceuticals Receives FDA Approval for DURLAZA™ (aspirin) Extended Release Capsules for Secondary Prevention of Stroke and Acute Cardiac Events September 08, 2015
News Industry News The Medicines Company Authorizes Generic Launch of ANGIOMAX® (bivalirudin) July 09, 2015